Reply to thread

Message: [QUOTE="Da_Aisijimo_Gou, post: 3782428, member: 264"] OCGN has not developed any SARS-2 vaccine. Instead, the 16 employee US company primarily blew up based on signing a prospective US development/distribution agreement with India's globally-respected Bharat Biotech (BICBL.BO). Longggggg long way to actually obtaining US FDA clearance, but time will tell. In India, Bharat's SARS-2 vaccine COVAXIN's completed Phase I and II trials with India's FDA. Currently, COVAXIN's only now in Phase III trials IN INDIA. At most, Bharat or its' new US partner, Ocugen, may have initiated discussions with the US FDA. However, neither company's started initial Phase I clinical trials in the States. Speaking of tiny biotechs with minimal current commercial products, questionable management and capital, it will be interesting in the new year to see whether FDAs in the US, UK, Canada and/or potentially The Philippines clear CYDY's Vyrologix for HIV, breast cancer, and potentially SARS-2 therapeutical treatment (long hauler and/or severe to critical care; now awaiting unblinding of Phase III trial results and potential FDA review/vote?). Vancouver, WA-based, OTC-only traded; Nasdaq if FDA cleared?; partnered with Samsung BioLogics for potential manufacturing. On top of vaccines, we sure could use more effective therapeuticals. [/QUOTE]